Glofitamab,Obinutuzumab,Tocilizumab
roche
['glofitamab']
many exciting updates from presentation today re glofitamab retreatment, development of subcut glofit, durability of responses ( i think people are cured but i don t know yet ) #ash22
haematology registrar | fellow @PORTAL_research @harvardmed |
evidence-based medicine | health policy | lymphoma | myeloma |
Fulbright scholar | muso | writer